Coeptis Therapeutics Stock (NASDAQ:COEP)

Revenue Ownership Financials Chart

Previous Close

$11.05

52W Range

$2.31 - $13.70

50D Avg

$9.38

200D Avg

$8.26

Market Cap

$38.95M

Avg Vol (3M)

$40.73K

Beta

-0.58

Div Yield

COEP Company Profile

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Dec 17, 2020

Website

COEP Performance

COEP Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-10.05M	$-21.49M	$-34.20M
Net Income	$-9.81M	$-21.27M	$-37.57M
EBITDA	$-10.05M	$-20.16M	$-36.35M
Basic EPS	$-5.10	$-0.83	$-2.87
Diluted EPS	$-5.10	$-0.83	$-2.87

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
LSB	LakeShore Biopharma Co., Ltd
HOTH	Hoth Therapeutics, Inc.
ICU	SeaStar Medical Holding Corporation
ZVSA	ZyVersa Therapeutics, Inc.
SPRC	SciSparc Ltd.
CVKD	Cadrenal Therapeutics, Inc. Common Stock
DRMA	Dermata Therapeutics, Inc.
CDIO	Cardio Diagnostics Holdings, Inc.